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Work Package 1
• Task 1.1 Design of Experiment
• Task 1.3 Design and characterisation of a set of SGIM 
reflecting the compositions of human GI fluids in the fasted 
and fed states
• Task 1.4 Optimisation and validation of novel small scale 
models for dissolution rate and apparent solubility in the 
designed SGIM
• Task 1.11 Determination of excipient effects on API behaviour
in developed in vitro models
Coverage
• Media Parameters
• Basic Experimental Protocol
• Design of Experiment Studies
• Four Component Mixture Design Studies
– Intestinal Solubility Topography
• Practical Application
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Khadra, I., et.al., (2015) Eur.J.Pharm.Sci., 67; 67-75


















(mM) Sodium TC 1.5 5.9 3.6 24 1.5 24
Lecithin 
(mM) Egg PL 0.2 0.75 0.5 4.8 0.2 4.8
Buffer (mM)
NaH2PO4 15 45 - - 15 45
Maleic acid - - 28.6 58.09 - -
Salt (mM) NaCl 68 106 125 203 68 203
pH NaOH/HCl 5 7 5 7 5 7
Enzyme 
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Media Parameters - Design of Experiment
• Fasted
– Fractional factorial design 
(quarter)
– 7 parameters





– 94 experiments (including 
duplicates)
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Khadra, I., et.al., (2015) Eur.J.Pharm.Sci., 67; 67-75
See also – Madsen, C., et.al., (2018) Eur.J.Pharm.Sci., 111; 311-319
Unpublished Data
Multiple – Design of Experiment Systems
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• 9 point Fasted and Fed
Khadra, I., et.al., (2015) Eur.J.Pharm.Sci., 67; 67-75
Zhou, Z., et.al., (2017) Eur.J.Pharm.Sci., 99; 95-104
Perrier, J., et.al., (2018) Eur.J.Pharm.Sci., 111; 247-256
Ainousah, B.E., et.al., (2017) Mol.Pharmaceutics 14; 4170-4180
9 Point – unpublished data
Impact DoE Design on Factor Significance













































































Smaller Design = Lower 
Factor Resolution
Four Component Mixture Design (4CMD)











Each Triangle – Ternary Phase Diagram
4CMD pH 7.4 TAC 11.7 mM
Aprepitant Carvedilol Zafirlukast
Fenofibrate Felodipine Spironolactone



























































































Nn Nn Nn = not normally distributed
• Indomethacin
Practical Application - BCS & DCS
Indomethacin
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Practical Application - Compartmental Analysis































































Practical Application – Prediction
Unpublished Data
Solubility
Overall Solubility Fasted Solubility
Pharmacokinetics
Experimental Caveats – Factor Concentrations





















































































































Khadra, I., et.al., (2015) Eur.J.Pharm.Sci., 67; 67-75
Fasted analysis onlyCholesterol
X
Experimental Caveats – Factor Ratios














pH 7 11.7 mM














pH 6 11.7 mM














pH 5 11.7 mM














pH 7 30.6 mM














pH 6 30.6 mM














pH 5 30.6 mM














pH 7 77.5 mM














pH 6 77.5 mM





















• 4CMD Amphiphile numb r & amphiphile ratio Fenofibrate
Conclusions
• Single media composition solubility measurement (SIF or HIF)– limited value
– Position within topography unknown, variability unknown
• Increase number of measurement points – increased information
– Big DoE – factor and solubility range information
– Wee DoE – solubility range – with caveats – limited or no factor information
• Choice of media components – the greater the better – see below
– Number, Concentration and Ratio – appropriate
• Beware – drug specific behavior
• Improved statistical information – HIF composition and SIF solubility
• Structured solubility behavior is present
• Solubility prediction – looking possible – limited initially
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